Non-Pharma Firms That Could Benefit From the GLP-1 Trend

Non-Pharma Firms That Could Benefit From the GLP-1 Trend highlights how the GLP-1 weight-loss boom extends beyond drug developers. The article notes that companies such as Novo Nordisk and Eli Lilly have built products including Ozempic and Zepbound, while investor attention is spreading to other players and to the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM). It argues that services and retail could gain as demand for GLP-1 treatments grows, projecting the market to triple in size in coming years. Teladoc Health is cited for its telehealth platform supporting obesity management and metabolic health, including GLP-1 prescription initiation. In Q1 2026, it beat revenue expectations by about $3 million to $614 million, with adjusted EBITDA of $58 million above guidance, alongside AI-enabled 24/7 offerings. The piece also points to Ollie’s Bargain Outlet (NASDAQ: OLLI), suggesting weight-loss-driven wardrobe replacement could support sales momentum. It references Teladoc’s plans for multi-step debt reduction and limiting stock-based compensation to $55 million or less, and a cash reserve of $751 million at end of Q1.